- Home
- CTMX vs CDTX Comparison
CTMX vs CDTX Comparison
Compare CTMX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- CDTX
- Stock Information
- Founded
- CTMX 2008
- CDTX 2012
- Country
- CTMX United States
- CDTX United States
- Employees
- CTMX N/A
- CDTX N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTMX Health Care
- CDTX Health Care
- Exchange
- CTMX Nasdaq
- CDTX Nasdaq
- Market Cap
- CTMX 89.1M
- CDTX 79.3M
- IPO Year
- CTMX 2015
- CDTX 2015
- Fundamental
- Price
- CTMX $0.89
- CDTX $20.40
- Analyst Decision
- CTMX Buy
- CDTX Strong Buy
- Analyst Count
- CTMX 6
- CDTX 5
- Target Price
- CTMX $5.77
- CDTX $30.50
- AVG Volume (30 Days)
- CTMX 1.1M
- CDTX 55.6K
- Earning Date
- CTMX 11-07-2024
- CDTX 11-07-2024
- Dividend Yield
- CTMX N/A
- CDTX N/A
- EPS Growth
- CTMX N/A
- CDTX N/A
- EPS
- CTMX 0.16
- CDTX N/A
- Revenue
- CTMX $126,617,000.00
- CDTX $44,653,000.00
- Revenue This Year
- CTMX $11.79
- CDTX N/A
- Revenue Next Year
- CTMX N/A
- CDTX N/A
- P/E Ratio
- CTMX $5.51
- CDTX N/A
- Revenue Growth
- CTMX 33.66
- CDTX 44.48
- 52 Week Low
- CTMX $0.83
- CDTX $10.00
- 52 Week High
- CTMX $5.85
- CDTX $24.40
- Technical
- Relative Strength Index (RSI)
- CTMX 35.66
- CDTX 87.39
- Support Level
- CTMX $0.84
- CDTX $12.89
- Resistance Level
- CTMX $1.08
- CDTX $13.78
- Average True Range (ATR)
- CTMX 0.07
- CDTX 1.14
- MACD
- CTMX -0.01
- CDTX 0.54
- Stochastic Oscillator
- CTMX 17.43
- CDTX 89.65
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.